Drug – bio-affecting and body treating compositions – Lymphokine
Reexamination Certificate
2008-09-16
2008-09-16
Mertz, Prema (Department: 1646)
Drug, bio-affecting and body treating compositions
Lymphokine
C530S324000, C536S023500, C435S069500, C435S071100, C435S325000, C435S252300, C435S320100
Reexamination Certificate
active
10510658
ABSTRACT:
Novel antagonists of MCP proteins, in particular of MCP-1 protein, can be obtained by generating MCP mutants whose GAG binding site, located at the N-terminal of MCP proteins, is eliminated following non-conservative substitutions. Compounds prepared in accordance with the present invention can be used in the treatment or prevention of diseases related to an undesirable activity of MCP proteins such, such as inflammatory disease, autoimmune diseases, vascular diseases, and cancer.
REFERENCES:
patent: 5094941 (1992-03-01), Hart
patent: 5116964 (1992-05-01), Capon et al.
Hemmerich et al (1999), Biochemistry, 38, pp. 13013-13025.
Mikayama et al. Proc. Natl. Acad. Sci. USA vol. 90, pp. 10056-10060.
Voet et al. Biochemistry John Wiley & Sons, Inc., pp. 126-128 and 228-234.
Eck & Wilson in Goodman & Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition, McGraw-Hill New York, 1996.
Hemmerich, S. et al. “Identification of residues in the monocyte chemotactic protein-1 that contact the MCP-1 receptor, CCR2”,Biochemistry, Oct. 5, 1999, pp. 13013-13025, vol. 38, No. 40.
Steitz, S. A. et al. “Mapping of MCP-1 functional domains by peptide analysis and site-directed mutagenesis”,FEBS Letters, Jul. 3, 1998, pp. 158-164, vol. 430, No. 3.
Seet, B. T. et al. “Molecular determinants for CC-chemokine recognition by a poxvirus CC-chemokine inhibitor”,Proceedings of the National Academy of Sciences of the United States, Jul. 31, 2001, pp. 9008-9013, vol. 98, No, 16.
Mayer, M. R. et al. “Identification of receptor binding and activation determinants in the N-terminal and N-loop regions of the CC chemokine eotaxin”,Journal of Biological Chemistry, Apr. 27, 2001, pp. 13911-13916, vol. 276, No. 17.
Chakravarty, L. et al. “Lysine 58 and histidine 66 at the C-terminal alpha-helix of monocyte chemoattractant protein-1 are essential for glycosaminoglycan binding”,Journal of Biological Chemistry, Nov. 6, 1998, pp. 29641-29647, vol. 273, No. 45.
Dawson, J. et al. “Targeting monocyte chemoattractant protein-1 signaling in disease”,Expert Opinion on Therapeutic Targets, Feb. 2003, pp. 35-48, vol. 7, No. 1.
Proudfoot, A. E. I. et al. “Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines”,PNAS, Feb. 18, 2003, pp. 1885-1890, vol. 100, No. 4.
Handel Tracy
Kosco-Vilbois Marie
Proudfoot Amanda
Laboratoires Serono SA
Mertz Prema
Saliwanchik Lloyd & Saliwanchik
LandOfFree
Antagonists of MCP proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antagonists of MCP proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antagonists of MCP proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3949768